IQE shares fall as FY25 core earnings slump 60% despite 2026 growth forecast

MACOM’s incremental capital commitment looks less like a generic rescue and more like a targeted option on InP supply chain control. The second-order implication is that the real asset is not IQE’s near-term earnings power but its role as a constrained upstream bottleneck in data-center photonics and AI interconnects; if that supply tightens, MACOM can protect gross margins and reduce dependency on third-party wafer availability. That also raises the bar for smaller compound-semiconductor peers: any customer fearing supply fragility may pre-emptively dual-source or sign longer contracts, which helps the whole InP ecosystem but concentrates bargaining power with the best-capitalized vertically integrated buyers.

The market is likely underappreciating how much of the 2026 guide is a balance-sheet story rather than a pure demand story. A high-single-digit to low-double-digit EBITDA outcome off a still-thin margin base leaves little room for execution slippage, and the fundraise plus debt cleanup only buys time if photonics ramps faster than wireless declines. The key risk window is the next 2-3 quarters: if the AI/datacenter order book doesn’t convert into sustained wafer volume, the company can still look ‘fixed’ while remaining structurally fragile.

Contrarian view: the stock may not be as cheap as the headline drawdown suggests because the equity raise changes the optics of per-share recovery. However, the presence of a strategic note buyer argues downside is more protected than a plain-cycle semiconductor name, so the better trade is not outright short equity but expressing skepticism via volatility or via relative-value against higher-quality compound semi exposure. The setup favors a catalyst-driven rerating if first-half 2026 bookings inflect, but absent that, the market will likely treat the guidance as a funding bridge rather than a durable inflection.